Showing results (401-410 of 427) with videos related to

Sort By:
Pageof 43
Hepatology (Baltimore, Md.)|November 22, 2020
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental CholangiocarcinomaLeticia Colyn, Marina Bárcena-Varela, Gloria Álvarez-Sola, et al.
Nature Reviews. Gastroenterology & Hepatology|February 9, 2023
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevanceDiego F Calvisi, Luke Boulter, Javier Vaquero, et al.
Nature Reviews. Gastroenterology & Hepatology|December 10, 2025
Cholangiocarcinoma 2026: status quo, unmet needs and prioritiesJesus M Banales, Pedro M Rodrigues, Silvia Affò, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 6, 2023
Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severityPhilip R Tedbury, Candela Manfredi, Frauke Degenhardt, et al.
Journal of the American Academy of Dermatology|March 3, 2020
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapiesAlan Menter, Joel M Gelfand, Cody Connor, et al.
JCI Insight|September 17, 2024
SLC4A11 mediates ammonia import and promotes cancer stemness in hepatocellular carcinomaAmeer L Elaimy, Marwa O El-Derany, Jadyn James, et al.
Hepatology (Baltimore, Md.)|June 13, 2025
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancementGuido Carpino, Diletta Overi, Rocio Ir Macias, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 26, 2022
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogrammingLeticia Colyn, Gloria Alvarez-Sola, M Ujue Latasa, et al.
Journal of Hepatology|March 3, 2023
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinomaAinhoa Lapitz, Mikel Azkargorta, Piotr Milkiewicz, et al.
Hepatology (Baltimore, Md.)|July 28, 2025
E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5pMaider Apodaka-Biguri, André L Simão, Francisco González-Romero, et al.
Pageof 43